promis™ neurosciences, inc. (tse: pmn, https://ca.finance.yahoo.com/q/bc?s=pmn.to), is a development stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular alzheimer’s disease (ad) and amyotrophic lateral sclerosis (als). the company’s scientific foundation centers on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. several neurodegenerative diseases exhibit protein misfolding, such as ad, als, and parkinson’s disease (pd). recent published evidence indicates that for a given misfolded protein there exist multiple prion-like strains, each strain representing a specific target against which specific therapeutics can be developed. the company is focused on the discovery and development of precision therapeutics and companion diagnostics to combat the several strains of beta-amyloid (aβ) and tau i